Recommendations for the transfusion of plasma and platelets

Blood Transfusion

Volumn 7, Issue 2, 2009, Pages 132-150

  Liumbruno, Giancarlo ^a,f   Bennardello, Francesco ^b   Lattanzio, Angela ^c   Piccoli, Pierluigi ^d   Rossetti, Gina ^e  

^a SAN GIOVANNI CALIBITA FATEBENEFRATELLI HOSPITAL   (Italy)

^b Azienda Ospedaliera Civile Maria Paterno Arezzo   (Italy)

^c Azienda Ospedaliera di Carbonara di Bari   (Italy)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

^e Azienda Ospedaliera di Trento   (Italy)

^f NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DETERGENT; FRESH FROZEN PLASMA; METHYLENE BLUE; THROMBOCYTE CONCENTRATE;

ACUTE LEUKEMIA; ALLOIMMUNIZATION; ANGIONEUROTIC EDEMA; AUTOIMMUNE THROMBOCYTOPENIA; BACTERIAL TRANSMISSION; BLADDER CANCER; BLOOD GROUP ABO SYSTEM; BLOOD TRANSFUSION REACTION; BONE MARROW APLASIA; BRAIN HEMORRHAGE; DISEASE TRANSMISSION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG FEVER; DRUG HYPERSENSITIVITY; HUMAN; HYPERVOLEMIA; INFECTION COMPLICATION; LIVER DISEASE; LIVER HEMORRHAGE; MYELODYSPLASTIC SYNDROME; PLASMA TRANSFUSION; PROPHYLAXIS; PURPURA; REVIEW; SEPSIS; SIDE EFFECT; SOLID TUMOR; THROMBOCYTE ANOMALY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPOIESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; TRANSFUSION RELATED ACUTE LUNG INJURY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VIRUS TRANSMISSION;

BLOOD COAGULATION DISORDERS; HEMORRHAGE; HUMANS; PLASMA; PLATELET TRANSFUSION; TREATMENT OUTCOME;

EID: 66349097846     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2009.0005-09     Document Type: Review

References (78)

1. Council of Europe. Guide to the Preparation, Use and Quality Assurance of Blood Components. Recommendation No R (95) 15 on the Preparation, Use and Quality Assurance of Blood Components, 14th ed, Strasbourg, Council of Europe Press; 2008.
2. Gazzetta Ufficiale della Repubblica Italiana - Serie Generale N. 85 del 13/04/05. Decreto Legislativo 3 Marzo 2005. Caratteristiche e modalità per la donazione di sangue e di emocomponenti.
3. Standards for Blood Banks and Transfusion Services, 24th ed, Bethesda, MD: American Association of Blood Banks; 2006.
4. British Committee for Standards in Haematology. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122: 10-23.
5. Patel IP, Ambinder E, Holland JF, Aldedort LM. In vitro and in vivo comparison of single-donor platelets and multiple-donor pooled platelet transfusions in leukemic patients. Transfusion 1978; 18: 116-119
6. Turner VS, Awker RJ, Mitchell SG, Seymour Mead AM. Paired in vitro and in vivo comparison of apheresis and recovered platelet concentrates stored for five days. J Clin Apher 1994; 9: 189-194
7. Heaton WA, Rebulla P, Pappalettera M, Dzik WH. A comparative analysis of different methods for routine blood component preparation. Transfus Med Rev 1997; 11: 116-129
8. Schiffer AC, Anderson KC, Bennet CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1519-1538
9. Prinoth O. Servizio Aziendale di Immunoematologia e Trasfusione - Comprensorio Sanitario di Bolzano. Terapia con emocomponenti e plasmaderivati. Linee guida ed aspetti medico-legali. January 2007. Available at: http://www.asbz.it/portal/it/document/IT/direzione/ LINEE%20GUIDA%20ALLA%20TRASFUSIONEITALIANE%20(integrale).pdf.
10. Superior Health Council. Guidelines for the transfusion of platelets (SCH 8068); 2005. Available at: http://www.health.fgov.be/CSH-HGR.
11. Practice parameters for the use of fresh-frozen plasma, cryoprecipitate, and platelets. Fresh-frozen plasma, cryoprecipitate, and platelets administration practice guidelines development task force of the College of American Pathologists. JAMA 1994; 271: 777-781
12. Istituto Superiore di Sanità. Rapporti ISTISAN 04/10. Atti del Convegno Nazionale Buon Uso del Sangue, Roma, 25-26 febbraio 2003. Available at: http//www.iss.it.
13. Hussein MA, Fletcher R, Long TJ, et al. Transfusing platelets 2 h after the completion of amphotericin-B decreases its detrimental effect on transfused platelet recovery and survival. Transfus Med 1998; 8: 43-47
14. Vorstand und wissenschaftlicher Beirat der Bundesärztekammer. Gefrorenes Frischplasma. In: Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten (Revision 2003). Deutscher Ärzte-Verlag, Köln; 2003.
15. Gmur J, Burger J, Schanz U, et al. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 1991; 338: 1223-1226
16. Pisciotto PT, Benson K, Hume H, et al. Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion 1995; 35: 498-502.
17. Gil-Fernandez JJ, Alegre A, Fernandez-Villalta MJ, et al. Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant 1996; 18: 931-935
18. American Society of Anesthesiologists Task Force on Blood Component Therapy. Practice guidelines for blood component therapy. Anesthesiology 1996; 84: 732-747
19. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997; 337: 1870-1875
20. Heckman KD, Weiner GJ, Davis CS, et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10,000/microl versus 20,000/microl. J Clin Oncol 1997; 15: 1143-1149
21. Wandt H, Frank M, Ehninger G, et al. Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukaemia. Blood 1998; 91: 3601-3606
22. Navarro JT, Hernandez JA, Ribera JM, et al. Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL. Haematologica 1998; 83: 998-1000.
23. Hunt BJ. Indications for therapeutic platelet transfusions. Blood Rev 1998; 12: 227-233
24. Menitove JE, Snyder EL. Platelet transfusion practice: time for renewed consensus [editorial]. Transfusion 1998; 38: 707-709
25. Contreras M. Final statement from the consensus conference on platelet transfusion. Transfusion 1998; 38: 796-797
26. Sagmeister M, Oec L, Gmur J. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood 1999; 93: 3124-3126
27. Lawrence JB, Yomtovian RA, Hammons T, et al. Lowering the prophylactic platelet transfusion threshold: a prospective analysis. Leuk Lymphoma 2001; 41: 67-76.
28. Rebulla P. Revisitation of the clinical indications for the transfusion of platelet concentrates. Rev Clin Exp Hematol 2001; 5: 288-310.
29. Rebulla P. Platelet transfusion trigger in difficult patients. Transfus Clin Biol 2001; 8: 249-254
30. World Health Organisation. The Clinical Use of Blood: Handbook, WHO; 2001.
31. Practice Guidelines for Blood Transfusion: A Compilation from Recent Peer-Reviewed Literature. American Red Cross 2002. Available at: http://chapters.redcross.org/br/indianaoh/hospitals/transfusion-guidelines.htm. re.
32. Callow CR, Swindell R, Randall W, Chopra R. The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy. Br J Hematol 2002; 118: 677-682
33. Benjamin RJ, Anderson KC. What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia? Crit Rev Oncol Hematol 2002; 42: 163-171
34. Friedman AM, Sengul H, Lehmann H, et al. Do basic laboratory tests or clinical observation predict bleeding in thrombocytopenic oncology patients? Transfus Med Rev 2002; 16: 34-45.
35. Zumberg MS, del Rosario ML, Nejame CF, et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hemopoietic stem cell transplant recipients: 10,000/microL versus 20,000/microL trigger. Biol Blood Marrow Transplant 2002; 8: 569-576
36. Stanworth SJ, Hyde C, Heddle N, et al. Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev 2004; 4: CD004269.
37. Heal MH, Blumberg N. Optimizing platelet transfusion therapy. Blood Reviews 2004; 18: 149-165
38. Stanworth SJ, Hyde C, Brunskill S, Murphy MF. Platelet transfusion prophylaxis for patients with haematological malignancies: where to now? Br J Haematol 2005; 131: 588-595
39. Wandt H, Schaefer-Eckart K, Frank M, et al. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37: 387-392
40. Webert KE, Cook RJ, Sigouin CS, et al. The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica 2006; 91: 1530-1537
41. British Committee for Standards in Hematology. Guidelines on the management of massive blood loss. Br J Haematol 2006; 135: 634-641
42. Levi M. Current understanding of disseminated intravascular coagulation. Br J Haematol 2004; 124: 567-576
43. British Committee for Standards in Hematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120: 574-596
44. Tinmouth AT, Semple E, Shehata N, Branch DR. Platelet immunopathology and therapy: a Canadian Blood Services research and development symposium. Transfus Med Rev 2006; 20: 294-314.
45. Roberts I, Murray NA. Neonatal thrombocytopenia: causes and management. Arch Dis Child Fetal Neonatal Ed 2003; 88: F359-64.
46. British Committee for Standards in Haematology. Transfusion guidelines for neonates and older children. Br J Haematol 2004; 124: 433-453
47. Andrew M, Castle V, Saigal S, et al. Clinical impact of neonatal thrombocytopenia. J Pediatr 1987; 110: 457-464
48. Andrew M, Vegh P, Caco C, et al. A randomised, controlled trial of platelet transfusions in thrombocytopenic premature infants. J Pediatr 1993; 123: 285-291
49. Blanchette VS, Kuhne T, Hume H, Hellmann J. Platelet transfusion therapy in newborn infants. Transfus Med Rev 1995; 9: 215-230
50. Del Vecchio A, Sola MC, Theriaque DW, et al. Platelet transfusions in the neonatal intensive care unit: factors predicting which patients will require multiple transfusions. Transfusion 2001; 41: 803-808
51. Roseff SD, Luban NLC, Manno CS. Guidelines for assessing appropriateness of pediatric transfusion. Transfusion 2002; 42: 1398-1413
52. Tripodi G, Antoncecchi S, Fanetti G, et al. Recommendations on transfusion therapy in neonatology. Blood Transfus 2006; 4: 158-180
53. Hellem AJ, Borchgrevink CF, Ames SB. The role of red cells in haemostasis: the relation between haematocrit, bleeding time and platelet adhesiveness. Br J Haematol 1961; 7: 42-50.
54. Livio M, Gotti E, Marchesi D, et al. Uraemic bleeding: role of anemia and beneficial effect of red cell transfusions. Lancet 1982; 2: 1013-1015
55. Small M, Lowe GD, Cameron E, Forbes CD. Contribution of the haematocrit to the bleeding time. Haemostasis 1983; 13: 379-384
56. Fernandez F, Goudable C, Sie P, et al. Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol 1985; 59: 139-148
57. Escolar G, Garrido M, Mazzara R, et al. Experimental basis for the use of red cell transfusion in the management of anemic-thrombocytopenic patients. Transfusion 1988; 28: 406-411
58. Burns ER, Lawrence C. Bleeding time. A guide to its diagnostic and clinical utility. Arch Pathol Lab Med 1989; 113: 1219-1224
59. Ho CH. The hemostatic effect of adequate red cell transfusion in patients with anemia and thrombocytopenia. Transfusion 1996; 36: 290.
60. Crowley JP, Metzger JB, Valeri CR. The volume of blood shed during the bleeding time correlates with the peripheral venous hematocrit. Am J Clin Pathol 1997; 108: 579-584
61. Valeri CR, Cassidy G, Pivacek LE, et al. Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss. Transfusion 2001; 41: 977-983
62. Eugster M, Reinhart WH. The influence of the hematocrit on primary haemostasis in vitro. Thromb Haemost 2005; 94: 1213-1218
63. Webert KE, Sigouin CS, Cook RJ, et al. Insights into the risk of bleeding in thrombocytopenic patients with acute leukaemia [abstract]. Transfusion 2005; 45 (Suppl 3): S33.
64. Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105: 4106-4114
65. Lozano M, Cid J. The clinical implication of platelet transfusions associated with ABO or Rh(D) incompatibility. Transfus Med Rev 2003; 17: 57-68.
66. Herman JH, King KE. Apheresis platelet transfusion: does ABO matter? [editorial]. Transfusion 2004; 44: 802-804
67. Josephson CD, Mullis NC, Van Demark C, Hillyer CD. Significant numbers of apheresis-derived group O platelet units have "high titer" anti-A/A,B: implications for transfusion policy. Transfusion 2004; 44: 805-808
68. Daly PA, Schiffer CA, Aisner J, Wiernik PA. Platelet transfusion therapy. One hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. JAMA 1980; 243: 435-438
69. O'Connell B, Lee EJ, Schiffer CA. The value of 10-minute post-transfusion platelet counts. Transfusion 1988; 28: 66-67
70. Bishop JF, Matthews JP, McGarth K, et al. Factors influencing 20-hour increments after platelet transfusion. Transfusion 1991; 31: 392-396
71. Contreras M. Diagnosis and treatment of patients refractory to platelet transfusions. Blood Rev 1998; 12: 215-221
72. Novotny VM. Prevention and management of platelet transfusion refractoriness. Vox Sang 1999; 76: 1-13.
73. Allford SL, Hunt BJ, Rose P, Machin SJ on behalf of the Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003; 120: 556-573
74. Keeling D, Davidson S, Watson H; Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. The management of heparin-induced thrombocytopenia. Br J Haematol 2006; 133: 259-269
75. British Committee for Standards in Haematology. Guidelines on the use of leucocyte-depleted blood components. Transfus Med 1998; 8: 59-71.
76. Ratko TA, Cummings JP, Oberman HA, et al. Evidence-based recommendations for the use of WBC-reduced cellular blood components. Transfusion, 2001; 41: 1310-1319
77. Ronghe MD, Foot ABM, Cornish JM, et al. The impact of transfusion of leucodepleted platelet concentrates on cytomegalovirus disease after allogeneic stem cell transplantation. Br J Haematol 2002; 118: 1124-1127
78. British Committee for Standards in Haematology. Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host-disease. Transfus Med 1996; 6: 261-271